Immunogenicity and Safety of Extended Dosing Intervals for Pfizer Pentavalent MenABCWY Meningococcal Vaccination in Healthy Adolescents: Results from a Randomized, Phase 2b Study
These data support Pfizer MenABCWY dosing flexibility and utility within the current or possible future US meningococcal vaccination framework.
Authors
- Y Liu
- Jake C. Jones
- Johannes Beeslaar (ORCID: https://orcid.org/0000-0003-0454-3515)
- Paula Peyrani (ORCID: https://orcid.org/0000-0001-8958-1734)
- Jason D. Maguire
- Roger Maansson
- Mary Tipton (ORCID: https://orcid.org/0000-0003-3002-521X)
- Paul Balmer (ORCID: https://orcid.org/0000-0001-8188-1791)
- Robert E. O’Neill
- Lefteris Zolotas
- Kelly Belanger
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Orthopedic Specialty Hospital (US)
- nView Medical (United States) (US)
Publication Details
- Journal
- Vaccines
- Published
- 2026-04-15
- DOI
- https://doi.org/10.3390/vaccines14040352
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer